135 related articles for article (PubMed ID: 25255650)
1. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
[TBL] [Abstract][Full Text] [Related]
2. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
Kaidar-Person O; Billan S; Kuten A
Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
[TBL] [Abstract][Full Text] [Related]
5. [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma].
Kuroda H; Sakurai T; Yamada M; Uemura N; Ono M; Abe T; Fujii S; Maeda M; Kohda K; Obata M; Ando M; Iyama S; Kato J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):627-30. PubMed ID: 21498992
[TBL] [Abstract][Full Text] [Related]
6. A Case of Metastatic Submandibular Salivary Duct Carcinoma that Completely Responded to Pembrolizumab Monotherapy.
Nakaishi M; Sakamoto K; Sakanushi A; Matsunobu T; Terasaki M; Okubo K
J Nippon Med Sch; 2023 Sep; 90(4):356-362. PubMed ID: 36273905
[TBL] [Abstract][Full Text] [Related]
7. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
11. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
Taha T; Billan S
Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
[TBL] [Abstract][Full Text] [Related]
12. Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases.
Fujimi A; Nagamachi Y; Yamauchi N; Nishisato T; Murase K; Takada K; Tsujiwaki M; Sugita S; Hasegawa T; Kato J
Oral Oncol; 2021 Sep; 120():105287. PubMed ID: 33858766
[No Abstract] [Full Text] [Related]
13. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
14. The role of trastuzumab in the management of salivary ductal carcinomas.
Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M
Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912
[TBL] [Abstract][Full Text] [Related]
15. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
16. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Sharon E; Kelly RJ; Szabo E
Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
[TBL] [Abstract][Full Text] [Related]
17. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
18. [A case of advanced breast cancer with multiple lung and liver metastases successfully treated with multi-disciplinary therapy].
Sakurai K; Enomoto K; Amano S; Kitajima A; Suzuki M; Matsuo S; Sakamoto A; Kashio M; Tani M; Negishi N
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1792-4. PubMed ID: 16315943
[TBL] [Abstract][Full Text] [Related]
19. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
van Boxtel W; Boon E; Weijs WLJ; van den Hoogen FJA; Flucke UE; van Herpen CML
Oral Oncol; 2017 Sep; 72():198-200. PubMed ID: 28673692
[No Abstract] [Full Text] [Related]
20. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
